The global spinal cord injury (SCI) treatment market is witnessing substantial growth, driven by advancements in medical technology, increased awareness, and the rising incidence of spinal cord injuries globally. SCI often results in permanent disability, making effective treatment crucial for improving patient quality of life. The market is benefiting from ongoing research in regenerative medicine, including stem cell therapy, as well as innovations in surgical techniques, neurostimulation devices, and drug development aimed at repairing spinal cord damage. Furthermore, the increasing focus on rehabilitation therapies and assistive devices is helping patients regain mobility and independence. The growing geriatric population and the rising number of road accidents, sports injuries, and falls are also contributing to market expansion.
The Global Spinal Cord Injury Treatment Market size was valued at USD 7.49 billion in 2023 and is projected to reach USD 11.15 billion by 2031, with a CAGR of 5.10% during the forecast period of 2024 to 2031.
To know more, visit https://www.databridgemarketresearch.com/reports/global-spinal-cord-injury-treatment-market
Below are the Top Spinal Cord Injury Treatment Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
Pfizer Inc.
|
Pfizer has been actively involved in developing treatments for spinal cord injuries (SCI), focusing on neuroregeneration and pain management. The company’s research includes efforts to address neurological disorders and muscle function, making it a key player in the development of SCI treatments.
|
|
North America, South America, Africa, Asia-Pacific, and Europe
|
In May 2019, Pfizer Inc. announced a Phase 3 study evaluating the use of LYRICA (pregabalin) as adjunctive therapy for epilepsy patients aged 5 to 65 years with primary generalized tonic-clonic (PGTC) seizures did not achieve its primary endpoint.
|
|
2.
|
Abbott
|
Abbott’s spinal cord injury treatment offerings include medical devices for neurostimulation and rehabilitation, along with innovative diagnostics. The company has pioneered advancements in spinal cord injury care through its neurostimulation technologies and rehabilitation solutions, focusing on quality of life improvements for SCI patients.
|
|
North America, Middle East and Africa, Asia-Pacific, and Europe
|
In May 2023, Abbott announced that FDA has approved its spinal cord stimulation (SCS) devices for the treatment of chronic back pain in people who have not had or are not eligible to receive back surgery, known as non-surgical back pain.
|
|
3.
|
Medtronic
|
Medtronic offers a range of spinal cord stimulation systems and implantable devices for pain management and neurostimulation. Medtronic’s expertise extends to spinal fusion procedures, providing comprehensive solutions for patients with SCI. Their innovative therapies aim to restore mobility and improve the quality of life for individuals suffering from spinal injuries.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In April 2024, the company received FDA approval for its Inceptiv™ closed-loop spinal cord stimulator, which automatically adjusts stimulation in real-time by sensing biological signals along the spinal cord.
|
|
4.
|
Novartis AG
|
Novartis is involved in research related to neurodegeneration and spinal cord regeneration, with ongoing efforts to develop innovative therapies that promote nerve regeneration and functional recovery in SCI patients. Their approach integrates cutting-edge gene therapies and cell therapies for spinal cord repair.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In March 2025, Novartis AG announced positive results from its Phase III clinical trials of intrathecal onasemnogene abeparvovec (OAV101 IT), an investigational gene therapy for spinal muscular atrophy (SMA). The trials demonstrated significant motor function improvements in patients aged 2 to under 18 years, with a favorable safety profile.
|
|
5.
|
Zimmer Biomet
|
Zimmer Biomet is a leading medical device company specializing in musculoskeletal healthcare. While well-known for its joint replacement and orthopedic solutions, Zimmer Biomet is also advancing spinal treatments, including spinal fusion technologies and surgical implants. The company’s spinal cord injury treatments focus on surgical interventions that aid in stabilizing and restoring spinal function.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In August 2024, Zimmer Biomet has signed an agreement to acquire OrthoGrid Systems, expanding its hip portfolio with OrthoGrid’s AI-driven Hip AI surgical guidance platform. The acquisition includes AI-powered fluoroscopy-based systems, enhancing surgical accuracy and efficiency.
|
Conclusion
The global spinal cord injury treatment market is expected to continue expanding, driven by innovations in regenerative medicine, surgical interventions, and rehabilitation technologies. As the global incidence of SCI rises, particularly among the aging population and due to increased trauma-related injuries, there is a growing demand for effective and advanced treatment options. While the market faces challenges such as high treatment costs and access barriers, ongoing advancements in SCI therapies and devices, along with rising healthcare awareness, are expected to drive continued growth in the market.
